Laura Airas
Affiliations: | 1990-1997 | Department of Immunology and Bacteriology | University of Turku, Åbo, Finland |
Google:
"Laura Airas"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Sirpa Jalkanen | grad student | 1990-1997 | University of Turku | |
| (Now Professor of Neurologgy) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Giovannoni G, Popescu V, Wuerfel J, et al. (2022) Smouldering multiple sclerosis: the 'real MS'. Therapeutic Advances in Neurological Disorders. 15: 17562864211066751 |
| Elo P, Li XG, Liljenbäck H, et al. (2021) Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis. Journal of Neuroinflammation. 18: 30 |
| Bezukladova S, Tuisku J, Matilainen M, et al. (2020) Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. Neurology(R) Neuroimmunology & Neuroinflammation. 7 |
| Airas L, Nylund M, Mannonen I, et al. (2020) Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. Multiple Sclerosis and Related Disorders. 40: 101980 |
| Elo P, Li XG, Liljenbäck H, et al. (2019) Folate receptor-targeted positron emission tomography of experimental autoimmune encephalomyelitis in rats. Journal of Neuroinflammation. 16: 252 |
| Kaasinen V, Joutsa J, Rissanen E, et al. (2019) Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders. 36: 101385 |
| Sucksdorff M, Tuisku J, Matilainen M, et al. (2019) Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurology(R) Neuroimmunology & Neuroinflammation. 6: e574 |
| Vainio SK, Dickens AM, Tuisku J, et al. (2019) Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. Ejnmmi Research. 9: 38 |
| Wolinsky J, Brochet B, Hartung H, et al. (2019) Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis Journal of the Neurological Sciences. 405: 31 |
| Högel H, Rissanen E, Barro C, et al. (2018) Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518819380 |